Janux Therapeutics (JANX) Consolidated Net Income: 2020-2025
Historic Consolidated Net Income for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$24.3 million.
- Janux Therapeutics' Consolidated Net Income rose 13.35% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of -$69.0 million for FY2024, which is 18.36% down from last year.
- Latest data reveals that Janux Therapeutics reported Consolidated Net Income of -$24.3 million as of Q3 2025, which was up 28.19% from -$33.9 million recorded in Q2 2025.
- Janux Therapeutics' Consolidated Net Income's 5-year high stood at -$2.3 million during Q1 2021, with a 5-year trough of -$33.9 million in Q2 2025.
- For the 3-year period, Janux Therapeutics' Consolidated Net Income averaged around -$19.0 million, with its median value being -$17.5 million (2023).
- In the last 5 years, Janux Therapeutics' Consolidated Net Income tumbled by 757.17% in 2021 and then soared by 65.96% in 2024.
- Quarterly analysis of 5 years shows Janux Therapeutics' Consolidated Net Income stood at -$13.4 million in 2021, then decreased by 19.75% to -$16.1 million in 2022, then rose by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then rose by 13.35% to -$24.3 million in 2025.
- Its Consolidated Net Income was -$24.3 million in Q3 2025, compared to -$33.9 million in Q2 2025 and -$23.5 million in Q1 2025.